300+ investors in your industry, stage, and region Get
Any industry
Video Games
Hospitality
EdTech
Restaurants
Google
Construction
Photography
Cryptocurrency
Clean Energy
CleanTech
Big Data
Email
Artificial Intelligence
Social Impact
SaaS
Energy
Consumer
Mobile
Enterprise Software
Health Care
Local
Platforms
InsurTech
Travel
Oil and Gas
Payments
Retail
Film
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
Facebook
Blockchain
B2B
Social Network
Medical Device
Education
Wellness
Sports
Biotechnology
Automotive
eSports
Software
Renewable Energy
Legal
Crowdfunding
Recruiting
Web3
Medical
Theatre
Venture Capital
Social
Infrastructure
Beauty
Fashion
Climate
LGBT
Cannabis
Celebrity
Life Science
Food and Beverage
Publishing
Mobile Apps
Wine and Spirits
Music
Art
Real Estate
Sporting Goods
Manufacturing
FinTech
Finance
Digital Media
Social Media
Financial Services
Franchise
Non Profit
Internet
Mobile Advertising
Android
Proptech
Impact
Sustainability
Hardware
Biotech
Transportation
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
Greece
United Kingdom
Thailand
United Arab Emirates
Andorra
Benin
South Korea
Burkina Faso
Africa
Singapore
Brazil
LATAM
Gibraltar
Egypt
Taiwan
Zimbabwe
Tunisia
Sweden
Oceania
Hong Kong
Nigeria
Togo
Croatia
Iran
Guinea
Haiti
Kyrgyzstan
Norway
Lesotho
Isle of Man
Liberia
Malawi
Nepal
Mexico
Madagascar
Russian Federation
Sudan
Pakistan
Tajikistan
Zambia
Romania
Japan
Oman
Puerto Rico
Poland
Cameroon
Guernsey
Armenia
Colombia
China
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Australia
New Zealand
Morocco
Saudi Arabia
Sri Lanka
Jamaica
Guatemala
Switzerland
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Turkey
Uruguay
Botswana
Moldova
Seychelles
Paraguay
Canada
South Africa
France
Denmark
Ireland
Georgia
Ghana
Iraq
Latvia
Mali
Malaysia
Philippines
Portugal
Rwanda
Sierra Leone
El Salvador
Senegal
Tanzania
United States
India
Germany
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Argentina
Spain
Europe
Qatar
Angola
Cyprus
Barbados
Belgium
Bangladesh
Jordan
Ethiopia
Austria
Azerbaijan
Bulgaria
Ecuador
Faroe Islands
Jersey
Bahrain
Estonia
Bolivia
Bahamas
Belize
Italy
Belarus
Finland
Hungary
Grenada
Israel
Lithuania
Honduras
Iceland
Cambodia
Liechtenstein
Lebanon
Algeria
Slovenia
Mongolia
Peru
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
Aier Eye Hospital Group, VC Fund

Aier Eye Hospital Group

VC Fund

Changsha, China

Aier Eye Hospital Group is a VC fund in Changsha focused on Medical Device and Medical. Aier Eye Hospital Group offers surgery for myopia; prevention and treatment for myopia; treatment for cataract, glaucoma, pediatric ophthalmology, fundus disease, lacrimal disease, and cornea and ocular surface; and eye shaping beauty services.

Total investments:
10
Last investment:
Lead investor:
30%

Last updated:

Industries Aier Eye Hospital Group invests in

Medical DeviceMedicalSoftwareHealth CareBiotechnology

Stages Aier Eye Hospital Group invests in

Series ASeries BPost-IPO EquitySeedSeries C

Countries Aier Eye Hospital Group invests in

ChinaHong Kong

Contacts

NameEmailPhoneSocials
Bang Chen
Li Li
Michael Lau

Sign up to unlock verified contacts

Unlock Contacts

Investment Focus

Industry

  • Medical Device 3 (30%)
  • Medical 2 (20%)
  • Software 2 (20%)
  • Health Care 2 (20%)
  • Biotechnology 2 (20%)
See all 18 industries →

Stage

  • Series A 2 (20%)
  • Series B 2 (20%)
  • Post-IPO Equity 2 (20%)
  • Seed 1 (10%)
  • Series C 1 (10%)
See all 7 stages →

Country

  • China 7 (70%)
  • Hong Kong 1 (10%)

Team

NameTitleInvestmentsLinksEmail
Bang Chen Founder
Founder Total investments: 0 Find email
Li Li Founder
Founder Total investments: 0 Find email
Michael Lau CEO
CEO Total investments: 0
Find email

Investments

CompanyDescriptionRoundLinks
Kangdesai Medical Technology Kangdesai Medical Technology
Kandesai is a personalized tumor immunotherapy developer, focusing on the development of immunotherapy platforms based on tumor neoantigens. It has independently developed 3 tumor drug pipelines based on neoantigens and innovative pipelines for liver cirrhosis with independent intellectual property rights. Help patients suppress tumor recurrenceand metastasis. Series A / Sep 22, 2025
Sieran Medical
Sieran Medical is a medical device company that provides precise and intelligent minimally invasive surgical treatment solutions for ophthalmology. $14.1M / Seed / Sep 05, 2024
Svision Svision
Svision is a healthcare start-up that develops and produces high-end ophthalmic imaging equipment. $43.1M / Series C / Mar 09, 2023
SIYO Bio-Tech SIYO Bio-Tech
SIYO Bio-Tech is a bioengineering company that focuses on research & innovation of microbial enzyme preparation technology. $31.7M / Series B / Feb 23, 2022
Svision Svision
Svision is a healthcare start-up that develops and produces high-end ophthalmic imaging equipment. Venture - Series Unknown / Dec 31, 2021
Zhaoke Ophthalmology Pharmaceutical Zhaoke Ophthalmology Pharmaceutical
Zhaoke Ophthalmology Pharmaceutical is a Pharmaceutical platform. $145M / Series B / Oct 12, 2020
The Kocla Smart Classes The Kocla Smart Classes
The Kocla Smart Classes provide centralized teaching and research services for education groups through the smart education platform, and enhance the interaction and communication between teachers, students, and parents through information technology. $5.1M / Post-IPO Equity / Mar 20, 2017
CloudClip CloudClip
CloudClip is a technology company that focuses on researching the myopia problem in young people and providing systematic solutions. They provide each user with customized eye-care training programs and help children develop a healthy eye-use habit. $1.4M / Series A / Dec 31, 2016
Qihoo 360 Technology Qihoo 360 Technology
Qihoo 360 Technology Co Ltd (Qihoo 360), formerly Qihoo Technology Company Limited, is engaged in the operations of Internet services and sales of third party anti-virus software in the People's Republic of China. It provides Internet and mobile security products in China. In January 2011, the Company had 328 million monthly active Internetsecurity product users, representing a user penetration rate of 83.9% in China. Its Internet and mobile security products include 360 Safe Guard and 360 Anti-virus, the Internet security products in China, with 301 million and 248 million monthly active users in January 2011, and 360 Mobile Safe, the mobile security product in China. The Company generates revenues primarily through offering the services, such as online advertising and Internet value-added services. Online advertising offers advertising services by providing marketing opportunities on its Websites and secure platform products to its advertising customers. $30M / Post-IPO Equity / Sep 28, 2016
The Kocla Smart Classes The Kocla Smart Classes
The Kocla Smart Classes provide centralized teaching and research services for education groups through the smart education platform, and enhance the interaction and communication between teachers, students, and parents through information technology. $7.1M / Series D / Jul 20, 2015

Co-Investors

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
Video Games
Hospitality
EdTech
Restaurants
Google
Construction
Photography
Cryptocurrency
Clean Energy
CleanTech
Big Data
Email
Artificial Intelligence
Social Impact
SaaS
Energy
Consumer
Mobile
Enterprise Software
Health Care
Local
Platforms
InsurTech
Travel
Oil and Gas
Payments
Retail
Film
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
Facebook
Blockchain
B2B
Social Network
Medical Device
Education
Wellness
Sports
Biotechnology
Automotive
eSports
Software
Renewable Energy
Legal
Crowdfunding
Recruiting
Web3
Medical
Theatre
Venture Capital
Social
Infrastructure
Beauty
Fashion
Climate
LGBT
Cannabis
Celebrity
Life Science
Food and Beverage
Publishing
Mobile Apps
Wine and Spirits
Music
Art
Real Estate
Sporting Goods
Manufacturing
FinTech
Finance
Digital Media
Social Media
Financial Services
Franchise
Non Profit
Internet
Mobile Advertising
Android
Proptech
Impact
Sustainability
Hardware
Biotech
Transportation
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
Greece
United Kingdom
Thailand
United Arab Emirates
Andorra
Benin
South Korea
Burkina Faso
Africa
Singapore
Brazil
LATAM
Gibraltar
Egypt
Taiwan
Zimbabwe
Tunisia
Sweden
Oceania
Hong Kong
Nigeria
Togo
Croatia
Iran
Guinea
Haiti
Kyrgyzstan
Norway
Lesotho
Isle of Man
Liberia
Malawi
Nepal
Mexico
Madagascar
Russian Federation
Sudan
Pakistan
Tajikistan
Zambia
Romania
Japan
Oman
Puerto Rico
Poland
Cameroon
Guernsey
Armenia
Colombia
China
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Australia
New Zealand
Morocco
Saudi Arabia
Sri Lanka
Jamaica
Guatemala
Switzerland
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Turkey
Uruguay
Botswana
Moldova
Seychelles
Paraguay
Canada
South Africa
France
Denmark
Ireland
Georgia
Ghana
Iraq
Latvia
Mali
Malaysia
Philippines
Portugal
Rwanda
Sierra Leone
El Salvador
Senegal
Tanzania
United States
India
Germany
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Argentina
Spain
Europe
Qatar
Angola
Cyprus
Barbados
Belgium
Bangladesh
Jordan
Ethiopia
Austria
Azerbaijan
Bulgaria
Ecuador
Faroe Islands
Jersey
Bahrain
Estonia
Bolivia
Bahamas
Belize
Italy
Belarus
Finland
Hungary
Grenada
Israel
Lithuania
Honduras
Iceland
Cambodia
Liechtenstein
Lebanon
Algeria
Slovenia
Mongolia
Peru
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does Aier Eye Hospital Group invest in?

Aier Eye Hospital Group invests primarily in Medical Device, Medical and Software startups, most often at Series A and Series B stage. Most of the 10 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

How do I contact Aier Eye Hospital Group?

Public channels for Aier Eye Hospital Group include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

Who are the partners at Aier Eye Hospital Group?

The team at Aier Eye Hospital Group includes Bang Chen (Founder), Li Li (Founder) and Michael Lau (CEO). The Team section lists each member with their title, investment count and links.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
Aier Eye Hospital Group Aier Eye Hospital Group Find emails